ProShares Ultra NASDAQ Biotechnology
BIB
BIB
19 hedge funds and large institutions have $3.4M invested in ProShares Ultra NASDAQ Biotechnology in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less call options, than puts
Call options by funds: $ | Put options by funds: $
less ownership
Funds ownership: →
less funds holding
Funds holding: →
39% less capital invested
Capital invested by funds: $5.59M → $3.4M (-$2.19M)
83% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 6
Holders
19
Holding in Top 10
–
Calls
$2.23M
Puts
$2.27M
Top Buyers
| 1 | +$1.35M | |
| 2 | +$52.3K | |
| 3 | +$37.5K | |
| 4 |
CG
Cutler Group
San Francisco,
California
|
+$23.4K |
| 5 |
AWM
Activest Wealth Management
Aventure,
Florida
|
+$17K |
Top Sellers
| 1 | -$2.43M | |
| 2 | -$645K | |
| 3 | -$290K | |
| 4 |
MCC
Money Concepts Capital
Palm Beach Gardens,
Florida
|
-$202K |
| 5 |
TFA
Toth Financial Advisory
Leesburg,
Virginia
|
-$27K |